Dose-dependent effects of methylene blue on hemodynamics, cytokines, oxidative stress, and organ dysfunction in a rat model of CLP-induced sepsis (2026)

Peer-Reviewed Study · Özcan Ö, Kara ŞŞ, Bal Özkaptan B, Öncü K, Şahin MH, Cabar HD, Tunçel ÖK, Sağır D · May 5, 2026

Özcan Ö et al., 2026-05-05: Animal dose-ranging study of methylene blue (10, 50 or 100 mg/kg IV) in septic rats, framed on the NO/sGC/cGMP pathway that methylene blue inhibits and its use as a catecholamine-sparing adjunct.

Septic shock involves excessive nitric oxide (NO) production and overactivation of the NO/sGC/cGMP pathway, leading to severe vasodilation and microvascular dysfunction. Methylene blue (MB), an inhibitor of this pathway, has been proposed as a catecholamine-sparing adjunct, yet optimal therapeutic dosing remains unclear.

Özcan Ö et al., 2026-05-05: Animal dose-ranging study of methylene blue (10, 50 or 100 mg/kg IV) in septic rats, framed on the NO/sGC/cGMP pathway that methylene blue inhibits and its use as a catecholamine-sparing adjunct. C6 (NO pathway, vasopressor interaction) and C5 (dose range). Funder/conflicts not stated in abstract. Comparator: sham/control and untreated sepsis. Animal doses here are far above human clinical doses and must not be read as human dosing; recorded for the mechanism and dose-response only. Abstract excerpt is two continuous sentences about the pathway, not the results. Study type: animal.